Role of erbB2 in breast cancer chemosensitivity.
Role of erbB2 in breast cancer chemosensitivity.
复制标题
DOI：
10.1002/1521-1878(200007)22:7
复制
发表时间：
2000-07
期刊：
影响因子：
--
通讯作者：
Dihua Yu;M. Hung
中科院分区：
文献类型：
--
作者：
Dihua Yu;M. Hung
编码跨膜生长因子受体的erbB2基因在大约30%的乳腺癌中过表达。过度表达该基因使乳腺癌对某些化疗药物产生耐药性。在这篇文章中，我们回顾了什么是已知的ErbB2介导的化疗耐药性和围绕它的争议。我们还检查了ErbB2的抗凋亡功能作为ErbB2介导的紫杉醇耐药的分子机制之一，并描述了几个新兴的策略，克服内在的ErbB2介导的化疗耐药性。最后，我们讨论了ErbB2过表达乳腺癌化疗敏感性研究的未来途径，这可能会导致有效的生物学为基础的治疗策略的发展。
The erbB2 gene, which encodes a transmembrane growth factor receptor, is overexpressed in approximately 30% of breast cancers. Overexpressing this gene makes breast cancers resistant to certain chemotherapeutic agents. In this article, we review what is known about ErbB2-mediated chemoresistance and the controversies surrounding it. We also examine the antiapoptotic function of erbB2 as one of the molecular mechanisms of ErbB2-mediated Taxol resistance and describe several emerging strategies for overcoming intrinsic ErbB2-mediated chemoresistance. Finally, we discuss future avenues for studies of chemosensitivity in ErbB2-overexpressing breast cancers that may lead to the development of effective biology-based treatment strategies.